论文部分内容阅读
目的评价应用茵栀黄注射液治疗婴儿肝炎综合征的疗效。方法计算机检索在Cochrane Central、PubMed、中国知网(CNKI)、万方数据库(Wanfang Data)、维普数据库(VIP),纳入茵栀黄注射液治疗婴儿肝炎综合征的临床随机对照试验,并对其进行质量评价,使用RevMan 5.0进行统计数据分析。结果共纳入4篇随机对照试验。在临床总疗效方面meta分析结果显示,OR=9.48,95%CI(4.05,22.18),在降低血清胆红素方面加权均数差(WMD)=-37.62,95%CI(-50.03,-25.21),缩小肝脏体积方面WMD=-0.86,95%CI(-1.59,-0.13),在降低血清中丙氨酸转氨酶活力(SALT)方面WMD=-20.72,95%CI(-29.38,-12.07),其差异均有统计学意义。结论与常规治疗组相比,茵栀黄注射液结合常规疗法治疗婴儿肝炎综合征疗效更佳,值得推广。
Objective To evaluate the curative effect of Yinzhihuang injection on infantile hepatitis syndrome. Methods A randomized controlled clinical trial was conducted to treat infantile hepatitis syndrome in Cochrane Central, PubMed, CNKI, VIP, VIP and Yinzhihuang injection. Conduct quality reviews and use RevMan 5.0 for statistical analysis. Results A total of 4 randomized controlled trials were included. In the overall clinical efficacy meta analysis, OR = 9.48,95% CI (4.05,22.18), weighted mean difference in reducing serum bilirubin (WMD) = -37.62,95% CI (-50.03, -25.21 WMD = -0.86, 95% CI (-1.59, -0.13) in reducing liver volume, WMD = -20.72, 95% CI (-29.38, -12.07) in reducing alanine aminotransferase activity (SALT) , The differences were statistically significant. Conclusion Compared with the conventional treatment group, Yinzhihuang injection combined with conventional therapy in the treatment of infantile hepatitis syndrome is more effective and worthy of promotion.